

Supplemental Table 1. Prevalence of opioid use disorder medication treatment of primary care patients with an opioid use disorder diagnosis across subgroups based on comorbid mental health and other substance use disorder diagnoses

	No mental health diagnoses or other substance use disorder		Other substance use disorder only		Mental health diagnosis only		Both mental health diagnoses and other substance use disorder	
	N= 1,605		N= 1,091		N= 4,530		N=6,753	
	Females	Males	Females	Males	Females	Males	Females	Males
	n=696	n=909	n=306	n=785	n=2,969	n=1,561	n=3,460	n=3,293
	%* (95% Confidence Interval)							
Any opioid use disorder treatment**	20.7 (17.8 - 23.5)	22.5 (20.1 - 25.0)	23.8 (19.9 - 27.6)	24.7 (22.2 - 27.2)	15.0 (13.7 - 16.3)	20.1 (18.2 - 22.0)	20.5 (19.2 - 21.7)	22.9 (21.6 - 24.2)
Buprenorphine	20.4 (17.6 - 23.3)	22.4 (19.9 - 24.8)	23.6 (19.7 - 27.5)	24.1 (21.7 - 26.6)	14.9 (13.5 - 16.2)	19.8 (17.9 - 21.6)	19.8 (18.6 - 21.0)	22.1 (20.8 - 23.3)
Injectable XR naltrexone	0.6 (0.02 - 1.3)	0.2 (0 - 0.6)	0.6 (0 - 1.3)	1.5 (0.7 - 2.2)	0.2 (0 - 0.4)	0.5 (0.1 - 0.8)	1.5 (1.1 - 1.9)	1.6 (1.1 - 2.0)

*Prevalence estimates (and 95% CIs) – adjusted for health system, age, and race-ethnicity – were obtained by fitting a logistic regression model and then applying marginal standardization

** defined as 1+ prescription or procedure code for buprenorphine formulations used to treat opioid use disorder (transmucosal, implants, sustained injection) and/or injectable XR naltrexone throughout the health system

Abbreviations: XR – extended release